Cas9gRNA-mIL30 targeting of IL30-overexpressing PCs in immunocompetent hosts decreases the recruitment of myeloid-derived cells, Tregs and ILC3s, inhibits NFKB1 expression, and hinders tumor progression. This evidence concerns the gene NFKB1 and neoplasm.